Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
about
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesLenalidomide for the treatment of B-cell lymphoma.L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Expression levels of TWIST1 are associated with the clinicopathological stage of B-cell non-Hodgkin lymphoma.Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaA comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.The evolving role of lenalidomide in non-Hodgkin lymphoma.A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.Trial Watch: Lenalidomide-based immunochemotherapy.Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.
P2860
Q26738937-4D36E68E-3E21-4D49-87E5-3378864CE3CFQ28540830-E71A03E4-D8FE-4093-B045-7085E1C81E11Q30249007-595FC297-AF02-486F-B84B-0E232F2E7DAEQ33439291-63456CAD-9211-43E3-B8D5-969DDDFB1CA4Q34292362-F6A96A02-BFDA-4BCA-914C-3394265806CDQ34819534-6598A38B-CF8B-4377-AE65-90556FDEE7A8Q38364912-1E2FE022-86FB-4CE0-AA8A-FAF8AA4317FBQ38594364-1310D02A-E63B-466E-8B7A-6AB07B3BB547Q38744704-45DFC41B-942F-4723-9052-D09244E48D5BQ39031363-91335469-6BE3-49FF-9225-BB9E425CBF77Q40831512-A98E31DF-124D-4C3B-8A51-33085610FBD3Q42737828-F1686F25-5C29-4B2C-AEE6-88B90B9BC0DDQ50976321-8400D4C4-A420-4988-B2A3-C13F5B74E8DF
P2860
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@ast
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@en
type
label
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@ast
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@en
prefLabel
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@ast
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@en
P2093
P2860
P1433
P1476
Rituximab, bendamustine, and l ...... sults of the SAKK 38/08 trial.
@en
P2093
K Eckhardt
S Berardi Vilei
Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
P2860
P304
P356
10.1007/S00277-013-1751-Z
P577
2013-04-17T00:00:00Z